Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

Regeneron develops and commercializes Libtayo globally. About Immuneering Corporation Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and ...

The EC approved Libtayo – a fully human monoclonal antibody ... therapeutics for the treatment of cancer. Meanwhile, another company focused on advanced cervical cancer is Nykode Therapeutics ...

Libtayo, too, underwhelmed in the first quarter ... I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational ...

Libtayo sales missed estimates. Regeneron has a tough road ahead, as it will take a long time for Eylea HD to contribute significantly to the top line. The company also suffered a few regulatory ...

The company also has an extremely full earlier ... Among oncology drugs, PD-1 antibody Libtayo is at the center, and is seeing solid growth (albeit from a smaller base) in niche indications ...

Based in Tarrytown, New York, the company’s products include EYLEA, Dupixent, Libtayo, Praluent, REGEN-COV, and Kevzara. More Top Stocks Daily: Go behind Wall Street’s hottest headlines with ...

The company believes that, based on the regulatory strategy ... The investigation will determine whether administering low doses of THIO prior to Libtayo can enhance and prolong the immune response in ...